Best Tirzepatide Providers in Virginia

Who pays for tirzepatide in Virginia?

It depends on who you work for, and each plan sets its own BMI bar for Zepbound® or Wegovy® for weight loss. Virginia Medicaid pays only above a BMI of 40, or 37 with a named condition (DMAS). State employees asking for the first time since July 1, 2026 need a BMI of 35 (DHRM). Medicare's GLP-1 Bridge starts at 35, or lower with certain conditions; TRICARE's form at 30, or 27 with a condition; VA health care for veterans at 27 with a condition. Job plans leave it to the employer, and the benchmark for Marketplace plans excludes weight-loss drugs. No plan pays for compounded tirzepatide, and MaxLife doesn't take insurance.

Pick your BMI range below to see whose bar it clears, then tap a plan for its details. Not sure of your BMI? Our BMI calculator works it out from your height and weight.

Military families: does TRICARE cover Zepbound or Wegovy?

Yes, for weight management, with conditions. TRICARE covers Wegovy®, Saxenda® and Zepbound® under TRICARE Prime, Prime Remote, the US Family Health Plan, TRICARE Select, Young Adult, Reserve Select, Retired Reserve and the Continued Health Care Benefit Program, if you meet its clinical criteria, have "a prescription from a network provider" and get prior authorization (TRICARE, updated August 6, 2026). Its prior authorization form, dated August 24, 2024, asks for a BMI of 30 or more, or 27 with diabetes, impaired glucose tolerance, dyslipidemia, high blood pressure or sleep apnea, after at least 6 months of diet and behavior changes (TRICARE form, Express Scripts).

Two groups are left out: TRICARE For Life members, who can look at Medicare's GLP-1 Bridge instead, and people with direct care coverage only. For them, TRICARE says, "You will pay 100% of the cost for your weight loss drugs even if you have an approved prior authorization." That line is about the groups it doesn't cover, not about Prime or Select members. TRICARE doesn't pay for compounded tirzepatide.

This matters in Virginia, home to 117,676 active-duty service members, the second most of any state, and 156,549 military family members, the most (Military OneSource, 2024 profile). TRICARE Open Season for Prime and Select runs from November 9 to December 8, 2026, and changes start January 1, 2027 (TRICARE Open Season).

Veterans: what VA health care covers

Here VA means the Department of Veterans Affairs. VA health care covers Zepbound® and Wegovy® for weight management under its criteria for use (April 2026): a BMI of 27 or more with at least one weight-related condition, such as high blood pressure, prediabetes, type 2 diabetes or sleep apnea, and documented participation in a comprehensive lifestyle program in the past year; "The MOVE! program is one example" (VA, Zepbound criteria; VA, Wegovy criteria). Inside VA care, a VA clinician prescribes and a VA pharmacy fills the prescription.

Virginia has three VA health care systems, based in Hampton, Richmond (Central Virginia) and Salem. About 623,000 civilian veterans live in Virginia, 9.0% of adults, the second-highest share of any state (Census Bureau, ACS 2025).

Federal employees and retirees: FEHB and PSHB plans

Every FEHB and PSHB plan covers at least one GLP-1 for weight loss and at least two oral weight-loss medicines, with prior authorization. New for 2027, "all FEHB and PSHB Carriers will require documented participation in an evidence-based intensive behavioral therapy (IBT) program both prior to and during treatment with anti-obesity medications," with 12 to 22 therapy sessions a year covered (OPM, 2027 Open Season highlights). Open Season runs from November 9 to December 14, 2026.

Each plan sets its own criteria. FEP Blue's 2026 Zepbound® policy asks for a BMI of 30, or 27 with heart disease or a weight-related condition, two oral weight-loss medicines first and a weight management program (FEP Blue policy 5.99.031), and its 2027 brochure lists "Drugs prescribed to treat obesity (prior approval required)" (FEP Blue, 2027 brochure). GEHA lists Wegovy®, Zepbound®, Saxenda® and Foundayo™ with prior authorization (GEHA, October 1, 2026).

If you left federal service, you aren't alone: federal jobs located in Virginia fell from 195,700 in January 2025 to 169,500 in September 2026, 26,200 fewer (13.4%; BLS, September preliminary). When FEHB ends you get a free 31-day extension. After that, Temporary Continuation of Coverage can keep you on FEHB for up to 18 months, counted from the day you left (not added after the extension), at the full premium, your share and the government's, plus a 2% administrative charge. People dismissed for gross misconduct can't use it (OPM). Ask a new plan whether it needs a new prior authorization.

State employees: COVA Care and the other state plans

For every state employee plan, new requests since July 1, 2026 need a BMI of 35: "A Body Mass Index (BMI) of 35 or higher is required to obtain a weight loss GLP-1 medication" (DHRM, Spotlight 2026). On August 12, 2026 DHRM softened it for people already on one: members "under an active PA, and remain continuously compliant, will not be required to meet the new BMI ≥ 35 criteria," and stay under the earlier rule, a BMI of 30, or 27 with high blood pressure, diabetes, dyslipidemia, sleep apnea or heart disease (DHRM, August 12, 2026). The plan's other prior authorization rules still apply, and the plan decides.

Since April 1, 2026, COVA Care, COVA HDHP and COVA HealthAware members can also use Virta, an online weight and metabolic health program (DHRM, March 25, 2026). If your doctor is with Sentara, read the Sentara and Anthem note under job plans: DHRM flagged it for state employees too.

Virginia Medicaid (Cardinal Care)

Yes, but the bar is high. Virginia Medicaid covers Wegovy®, Zepbound® and other GLP-1s for weight loss with service authorization when your BMI is over 40, or over 37 with dyslipidemia, high blood pressure or type 2 diabetes. You also need a failed trial of an older non-GLP-1 weight-loss drug (or intolerance to all of them), a trial of the preferred product, nutrition counseling and a physical activity program, and your provider must attest that the obesity is "disabling and life threatening." Approvals last 6 months, renewals need 5% weight loss, and "Renewals will no longer be granted once a member reaches a BMI < 25." For Zepbound®, the member "must try and fail Zepbound KwikPen prior to approval of Zepbound unit dose pen" (DMAS form, effective October 20, 2026). In 2024 DMAS told lawmakers, "All MCO and FFS share the same criteria," so every Medicaid health plan follows these rules (DMAS, RD208).

Will it change? The 2026 to 2028 budget tells DMAS to look for a GLP-1 deal at "a net price per one-month supply of $245 or less" and to switch to the federal BALANCE Model's criteria if that deal saves the most; otherwise the BMI 40 and 37 rule stays (2026 budget, Item 291). We found no DMAS decision yet, so plan on today's rule. Cover Virginia answers questions in Spanish and other languages at 1-855-242-8282 (Cover Virginia).

Medicare: the GLP-1 Bridge, $50 a fill

Medicare drug plans can't pay for weight loss, but from July 1, 2026 to December 31, 2027 the Medicare GLP-1 Bridge charges $50 a fill for Wegovy® (injection or tablet), Foundayo™ or the Zepbound® KwikPen® (not Zepbound® vials or single-dose pens). You qualify with a BMI of 35 or more; 30 or more with diastolic heart failure, uncontrolled high blood pressure or chronic kidney disease (stage 3a or higher); or 27 or more with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease, and your provider certifies a diet and exercise program (Medicare.gov). People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease use their Part D plan instead.

In July 2026, 1,759,388 Virginians had Medicare, and 1,310,622 of them (74.5%) had Part D drug coverage (CMS). Open enrollment runs to December 7 for coverage from January 1 (Medicare.gov, joining a plan), and VICAP, Virginia's free Medicare counseling program, answers at 1-800-552-3402 (CMS directory). The Bridge doesn't cover compounded tirzepatide.

Job plans, and Sentara and Anthem

Your employer decides. A plan's drug list can name Zepbound® or Wegovy® and still not pay for weight loss if the employer left weight-loss drugs out. Plans that use CVS Caremark could add Zepbound® back from October 1, 2026, "for plan sponsors who elect to provide coverage of those medications" (CVS Health, May 28, 2026). Ask HR, or check your plan's drug list and benefits booklet for a weight-loss exclusion. If your plan covers it, Virginia law gives insurers two business days to answer a complete prior authorization request, or 24 hours if it's urgent (Code of Virginia § 38.2-3407.15:2).

Hampton Roads has a network question on top. Sentara gave Anthem notice on July 31, 2026 (Sentara), and on October 5, 2026 it ended talks for Anthem's Medicare Advantage, Medicaid and Marketplace plans (WTKR). Unless a deal is reached, Sentara goes out of network for those Medicare Advantage and Marketplace members on January 1, 2027. Medicaid members keep Sentara in network through January 27 and lose it on January 28, 2027 (Sentara, updated October 29, 2026; Anthem). Employer plans are negotiated separately, and Sentara says they aren't affected by this change. Anthem lists its employer-plan contracts with Sentara as ending December 31, 2026 for the Tidewater and Eastern Virginia facilities, physician groups and ancillary providers, and December 31, 2027 for the other facilities. If your prescriber is with Sentara and your plan is Anthem, state employee plans included, ask before January whether your prior authorization carries over.

Virginia's Insurance Marketplace

Virginia runs its own exchange. Open enrollment for 2027 runs from November 1, 2026 to January 29, 2027 (Virginia's Insurance Marketplace); enroll by December 31 for coverage from January 1 (Marketplace Help Center). New this year, Virginia Premium Savings lowers premiums for households earning 138% to 250% of the federal poverty level; "An estimated 200,000 Virginians may qualify" (Virginia Premium Savings). Weight-loss drugs are a different matter: Virginia's benchmark plan for 2025 to 2027 lists "Weight loss drugs" as not covered (CMS), so most Marketplace plans leave them out. Check a plan's drug list before you pick it.

If your plan says no

Appeal to your plan first. If a fully insured Virginia plan denies a covered drug as not medically necessary, the State Corporation Commission's Bureau of Insurance offers a free external review, decided within 45 days (72 hours if expedited), and the decision binds the insurer (SCC, external review). It can't overturn a plan exclusion: the SCC lists "contractual exclusions" among ineligible reasons. Medicare, Medicaid, TRICARE, federal employee plans and self-funded plans that haven't opted in have their own appeals (Code of Virginia § 38.2-3557).

What tirzepatide costs in Virginia

Paying cash, the online programs in our table charge about $120 to $235 a month for compounded tirzepatide, depending on how long you commit, and Virginia practices with published prices start at $275 to $350 a month before first-visit and lab fees. Brand Zepbound® from LillyDirect costs $299 at the starting dose, $399 at the next and $449 at higher doses when you refill within 45 days, before visit fees and needles; late refills cost $499 or $699.

What a year costs depends on the plan's length and whether the price climbs with the dose. The bars show 12 months on each program's own published prices. On Medicare, the GLP-1 Bridge's $50 a fill comes to $650 for 13 fills if you qualify.

Online visits and who can prescribe in Virginia

Virginia lets you start care online, and its boards expect a live, real-time visit before the first prescription. The Code of Virginia lets a prescriber set up care through "face-to-face interactive, two-way, real-time communications services or store-and-forward technologies" when a list of conditions is met, including the in-person standard of care and a Virginia license (Code of Virginia § 54.1-3303). The Board of Medicine says a prescription "based solely on an online questionnaire" is not an acceptable standard of care (Guidance 85-12, 2021), and the joint guidance of the Boards of Medicine, Nursing and Pharmacy, effective October 8, 2026, adds: "If the patient has not interacted in real-time with the prescriber, then a valid practitioner-patient relationship has not been established" (Guidance 76-1). Once you're a patient, follow-ups by message are fine.

In Virginia, a licensed provider reviews your online intake and health history and then meets you by live video before a first prescription, as Virginia's boards expect. Follow-ups can be by message. Completing the intake doesn't guarantee a prescription.

Whoever prescribes needs a Virginia license: a physician (MD or DO) or a physician assistant working under a practice agreement, both licensed by the Virginia Board of Medicine (§ 54.1-2951.1), or a nurse practitioner with a joint license from the Boards of Medicine and Nursing. Since a 2024 law, nurse practitioners with three years of full-time experience can practice without a practice agreement (§ 54.1-2957). Virginia joined the Nurse Licensure Compact on January 19, 2018 (NCSBN), which covers registered and practical nurses, not prescribing. Virginia isn't a member of the Interstate Medical Licensure Compact for physicians (IMLCC member map, October 2026).

Virginia once had a weight-loss prescribing rule that reached GLP-1s, with an exam, labs and a visit within 30 days. The Board of Medicine repealed it effective February 27, 2025, so the general standard of care applies (Virginia Register).

Is compounded tirzepatide legal in Virginia?

It can be, under conditions. A prescriber licensed in Virginia must order it for you, and a pharmacy licensed or registered by the Virginia Board of Pharmacy must make it from a prescription in your name. It is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients, and Virginia's boards say so too: "The Boards note that compounded drugs are not FDA-approved" (Guidance 76-1).

What ended is routine copying. The FDA declared the tirzepatide shortage over on December 19, 2024, and a federal appeals court upheld that on August 27, 2026. The grace period ended on March 5, 2025 for state-licensed (503A) pharmacies and on March 19, 2025 for outsourcing facilities (503B) (FDA).

Virginia's compounding law bars "the regular compounding or the compounding of inordinate amounts of any drug products that are essentially copies of commercially available drug products," with exceptions that include "a change in the product ordered by the prescriber for an individual patient," and requires USP compounding standards (Code of Virginia § 54.1-3410.2). Ask any program which pharmacy fills its prescriptions and how that pharmacy meets the rule.

The boards also put med spas and IV clinics on notice in October 2026: clinics that "allow patients to select treatments from a menu, complete a brief questionnaire, and undergo a basic screening by a nurse or unlicensed staff member may be operating in an illegal and unsafe manner," only licensed staff may give injections, and medicine labeled "for research purposes only" is unlawful for these clinics to possess (Guidance 76-1). Don't buy tirzepatide sold for research.

Pharmacies that ship compounded tirzepatide to Virginia

A pharmacy outside Virginia that mails prescription drugs here must hold a nonresident registration from the Virginia Board of Pharmacy for each site, with a pharmacist in charge licensed in Virginia, a recent inspection report showing it meets USP compounding standards and a toll-free line to a pharmacist on every label. If more than half its prescriptions come from internet solicitation, it also needs NABP's Verified Internet Pharmacy Practice Site certification (Code of Virginia § 54.1-3434.1). The Board expects every pharmacy to ship at the right temperature (Board of Pharmacy Guidance 110-46).

More of Virginia's medicine comes by mail. Out-of-state pharmacies registered to ship here rose from 524 in 2014 to 962 in 2024 (up 83.6%), while Virginia's own pharmacy permits fell from 1,796 to 1,737 (down 3.3%); the out-of-state share of all pharmacy licenses grew from 22.6% to 35.6% (DHP biennial reports). Rite Aid had 64 Virginia stores in 2023 (Patch) and closed them all by October 2025, sending prescriptions to CVS, Kroger, Harris Teeter and Walgreens (Patch, October 16, 2025); DHP License Lookup lists no current Rite Aid pharmacy permit.

Tirzepatide across Virginia, region by region

Need is highest where care is thinnest. Estimated adult obesity runs from 27.2% in Northern Virginia to 41.9% in Southside, which also has the lowest share of homes with broadband (77.1%); statewide it was 34.2% in 2025 (CDC, BRFSS). Petersburg's estimate (46.6%) is the highest of Virginia's 133 counties and independent cities and Fairfax County's (23.8%) the lowest (CDC PLACES). About 2.1 million Virginians live in federal primary care shortage areas (HRSA), and online care with mail delivery reaches all of them.

The map uses GO Virginia's nine regions (Virginia DHCD). Virginia's 38 independent cities belong to no county; each is counted in the region it sits in.

Summer heat, winter storms and deliveries

Heat is Virginia's bigger delivery risk. In summer 2026, Danville logged 93 days at 86°F or hotter out of 122, Emporia 92 and Richmond 83, and Reagan National in Arlington hit 103°F on July 4 (NOAA). 86°F is the room-temperature limit on the Zepbound® label, and Zepbound® must never freeze (Lilly); compounded tirzepatide follows its own pharmacy label.

Winter still matters, mostly in the west and the Valley. Winchester logged 85 nights at or below 32°F out of 90 last winter, and the January 2026 storm brought a statewide emergency (Executive Order 11, January 22, 2026) and a federal emergency declaration for all 133 counties and independent cities (FEMA). Hurricane Helene's floods in September 2024 led to a federal disaster declaration for 37 localities, most of them in Southwest Virginia (FEMA).

Every mailed prescription must come with a written notice that drugs can degrade and a phone number for questions (§ 54.1-3420.2). If you run out and can't reach your prescriber, a pharmacist may refill a prescription only when your health "would be in imminent danger" without it (§ 54.1-3411), so order before a storm. Ask for expedited shipping, bring the box in as soon as it arrives, and call the pharmacy if it's warm or frozen.

What MaxLife offers Virginians

MaxLife is a telehealth company in Irvine, California that serves all 50 states, Virginia included, by mail; we have no Virginia office. Compounded tirzepatide costs $120 a month, flat: all-inclusive and the same price at every dose, with no membership fee and no hidden fees. The provider review and video visit, ongoing support, medicine if prescribed, supplies and free expedited shipping in an insulated container are included, and a licensed partner pharmacy authorized to serve Virginia fills the prescriptions. Billed every 3 months at the flat price ($360); cancel anytime with notice before your next billing period.

In Virginia, a licensed provider reviews your online intake and health history and then meets you by live video before a first prescription, as Virginia's boards expect. Follow-ups can be by message. Completing the intake doesn't guarantee a prescription.

About 649,000 Virginians speak Spanish at home (7.9% of people 5 and older), with the highest shares in Manassas Park, Manassas, Sterling and Woodbridge (U.S. Census Bureau). MaxLife has Spanish-speaking staff who can guide you through the program and support you during treatment.

If TRICARE, VA health care, a federal or state plan, Medicaid, Medicare's Bridge or an employer weight-loss benefit covers Zepbound® or Wegovy® for you, your copay may be lower than paying cash. MaxLife is a patient management platform, not a pharmacy or a drug maker, and independent licensed providers decide whether a prescription is right for you.